Viewing Study NCT06708858


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2026-01-31 @ 4:53 AM
Study NCT ID: NCT06708858
Status: RECRUITING
Last Update Posted: 2024-11-27
First Post: 2024-11-11
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Sponsor: Dai, Guanghai
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Biliary Tract Cancer View
Keywords: